middle.news
NeuroScientific’s StemSmart™ Shows Early Promise in Tough Crohn’s Cases
8:49am on Friday 30th of January, 2026 AEDT
•
Biotechnology
Read Story
NeuroScientific’s StemSmart™ Shows Early Promise in Tough Crohn’s Cases
8:49am on Friday 30th of January, 2026 AEDT
Key Points
Positive clinical responses observed in 3 of 4 patients treated under Special Access Program
Phase 2 clinical trial design informed by real-world treatment data
Manufacturing technology transfer progressing to support scale-up
New Clinical & Scientific Advisory Board appointed to guide development
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuroscientific Biopharmaceuticals (ASX:NSB)
OPEN ARTICLE